Walden Biosciences Announces Participation at October Investor Conferences
13 Oct 2022
AntibodySmall molecular drug
Walden Biosciences Announces Participation at October Investor Conferences
Presentations to highlight transformational, disease-modifying approach to treating kidney diseases
CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that Blaine McKee, Ph.D., President and Chief Executive Officer of Walden Biosciences, will be participating in the following investor conferences during the month of October:
Oppenheimer Healthcare Private Company Showcase: The Next Wave
Format: Company Presentation and 1x1 Investor Meetings
Date: October 18, 2022
Company Presentation Time: 1:30 p.m. PST
Location: Palo Alto, CA
Needham Biotech Private Company 1x1 Forum
Format: 1x1 Investor Meetings
Date: October 19, 2022
Location: Virtual
SVB Securities Biopharma Private Company Connect
Format: 1x1 Investor Meetings
Date: October 26-28, 2022
Location: Virtual
About Walden Biosciences
Walden Biosciences is focused on developing breakthrough medicines to treat both rare and common forms of kidney disease. Founded by world-renowned renal experts, Walden is applying novel, multi-disciplinary approaches that directly target the kidneys to prevent damage, slow disease progression, and restore kidney function. Walden’s programs address two novel targets for therapeutic intervention, directly targeting two cell types in the kidney: podocytes and proximal tubular cells. Dysfunction of these cells are critical hallmarks of the majority of renal diseases. Walden’s most advanced program is a humanized antibody that inhibits soluble urokinase plasminogen activating receptor, or suPAR, a pro-inflammatory mediator that causes podocyte dysfunction and renal disease. Walden’s second program is a small molecule that is designed to restore the function of dynamin, an enzyme responsible for the maintenance of the cytoskeletal architecture of podocytes and proximal tubule cells. Both programs offer the promise to deliver disease-modifying, breakthrough therapies to transform the treatment of renal disease. Walden was launched in late 2020 with a $51 million Series A round of financing led by Arch Venture Partners with participation from other leading venture capital firms. For more information, please visit www.waldenbiosciences.com.
Investor Contact:
Stern Investor Relations
Anne Marie Fields
Managing Director
annemarie.fields@sternir.com
Media Contacts
Robert Stanislaro
Robert.Stanislaro@fticonsulting.com
-OR-
Helen O’Gorman
Helen.O’Gorman@fticonsulting.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.